Poor treatment outcomes among multidrug-resistant tuberculosis patients in Gomel Region, Republic of Belarus

Khaliaukin, A.; Kumar, Ajay M. V.; Skrahina, Alena; Hurevich, Henadz; Rusovich, Valiantsin; Gadoev, Jamshid; Falzon, Dennis; Khogali, Mohammed; Colombani, Pierpaolo de

doi:10.5588/pha.14.0042

Cited by 17 publications

(16 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…20,21 Such patients are very difficult to manage and are more at risk of adverse outcomes. The NTP needs to control the irrational use of SLDs and take firm steps to ban over-the-counter sales of both FLDs and SLDs.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Did diabetes mellitus affect treatment outcome in drug-resistant tuberculosis patients in Pakistan from 2010 to 2014?

Latif¹,

Ghafoor²,

Wali

et al. 2018

public health action

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…20,21 Age-specific treatment strategies are needed to improve outcomes in older age patients. We also observed that patients with a history of anti-tuberculosis treatment in the private sector were more likely to have unfavourable treatment outcomes than those treated in the public sector (OR 1.53, 95%CI 1.16-2.02).…”

Section: Discussionmentioning

confidence: 99%

Did diabetes mellitus affect treatment outcome in drug-resistant tuberculosis patients in Pakistan from 2010 to 2014?

Latif¹,

Ghafoor²,

Wali

et al. 2018

public health action

View full text Add to dashboard Cite

“…However, a 2012 individual patient data meta-analysis found a higher proportion of 23% [26]. A rough literature review has revealed that the proportion of MDR TB patients who were LTFU ranges from 2.2 to 47% [27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43]. The figures vary vastly among different years, countries, and institutions, suggesting that the underlying factors responsible for these variations should be studied carefully.…”

Section: Proportion Of Ltfumentioning

confidence: 99%

Loss to Follow-Up (LTFU) during Tuberculosis Treatment

Lin¹

2019

Healthcare Access - Regional Overviews [Working Title]

View full text Add to dashboard Cite

Loss to follow-up (LTFU) is a serious issue in the field of tuberculosis (TB) since it can lead to TB outbreaks and drug resistance. The proportion of LTFU patients differs among different countries, regions, year, and institutions. In some countries, the number of patients that were LTFU nearly reaches half of the total patients. Underlying factors such as age, gender, education, residence, financial factors, migration, and social stigma are discussed in this chapter. These factors should always be taken into consideration whenever a treatment program is designed. Suggestions have been made regarding some interventions that could potentially solve the problem of LTFU. With these points in mind, an ambitious approach should be taken to reduce the number of LTFU patients up to zero.

show abstract

“…XDR-TB can be primarily transmitted from person to person or secondary to the development through high bacillary load, inadequate treatment (poor compliance, iatrogenic, drug stock outs, programatic weakness), low body mass index, or previous failures [34][35][36][37][38]. Prevention of the development of drug-resistant TB is essential given the recent worldwide increase in incidence.…”

Section: Prevention Of Xdr-tb During Mdr-tb Treatmentmentioning

confidence: 99%

Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers

Alffenaar

Akkerman

Anthony

et al. 2016

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Introduction: Success rates for treatment of extensively drug resistant tuberculosis (XDR-TB) are low due to limited treatment options, delayed diagnosis and inadequate health care infrastructure. Areas covered: This review analyses existing programmes of prevention, diagnosis and treatment of XDR-TB. Improved diagnostic procedures and rapid molecular tests help to select appropriate drugs and dosages. Drugs dosages can be further tailored to the specific conditions of the patient based on quantitative susceptibility testing of the M. tuberculosis isolate and use of therapeutic drug monitoring. Pharmacovigilance is important for preserving activity of the novel drugs bedaquiline and delamanid. Furthermore, biomarkers of treatment response must be developed and validated to guide therapeutic decisions. Expert commentary: Given the currently poor treatment outcomes and the association of XDR-TB with HIV in endemic regions, a more patient oriented approach regarding diagnostics, drug selection and tailoring and treatment evaluation will improve treatment outcome. The different areas of expertise should be covered by a multidisciplinary team and may involve the transition of patients from hospitalized to home or community-based treatment.

show abstract

Poor treatment outcomes among multidrug-resistant tuberculosis patients in Gomel Region, Republic of Belarus

Cited by 17 publications

References 14 publications

Did diabetes mellitus affect treatment outcome in drug-resistant tuberculosis patients in Pakistan from 2010 to 2014?

Did diabetes mellitus affect treatment outcome in drug-resistant tuberculosis patients in Pakistan from 2010 to 2014?

Loss to Follow-Up (LTFU) during Tuberculosis Treatment

Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers

Contact Info

Product

Resources

About